The following posters will be displayed during Poster Session A on Friday, June 5 from 11:30 AM-12:00 PM

and the Welcome and Poster Reception on Friday, June 5 from 4:15 PM-6:00 PM

*Poster Tour A will take place on Friday, June 5 from 12:00 PM-12:30 PM (posters listed below with a * will be on the tour)

*1 – Efficacy and Safety of Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Consistent Outcomes Across Levodopa Equivalent Dose Groups in a Phase 3 Open-Label Study

Brett Himmler, Jason Aldred, Angelo Antonini, Jaclyn Homola, Resmi Gupta, Olga Kozanian, Sarah Hnath, Koray Onuk, Shannon Shaffer, Victor SC Fung

2 – Heat Map Visualization of Improved Best ON Time in People With Parkinson’s Disease Treated With Foscarbidopa/Foslevodopa

Brett Himmler, Tove Henriksen, Robert A. Hauser, Irene Malaty, Thomas E. Kimber, Michael J. Soileau, Lars Bergmann, Linda Harmer, Jaclyn Homola, Resmi Gupta, Connie H. Yan, Bruno Bergmans

3 –Real-World Safety and Effectiveness of Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results

Brett Himmler, Wolfgang H Jost, Filip Bergquist, Andrew Evans, Sharon Hassin-Baer, Robert Hauser, Tove Henriksen, Irene Malaty, Tiago Mestre, Pablo Mir, Ramon Rodriguez, Petra Schwingenschuh, Mihaela Simu, Lars Bergmann, Pavnit Kukreja, Marie O’Meara, Juan Carlos Parra, Megha Shah, Jason Aldred

4 – Clinical Effects of Perampanel in Parkinson’s Disease: Evidence from Controlled Trials

Jamir Pitton Rissardo, Jorge Patino, Ana Fornari Caprara, Ian M. Walker

5 – Effects of Traditional Acupuncture on Motor and Nonmotor Symptoms in Parkinson’s Disease: A Placebo‑Controlled Meta‑analysis

Jamir Pitton Rissardo, Jorge Patino, Ana Fornari Caprara, Ian M. Walker

6 – Efficacy and Safety of Curcumin Supplementation in Parkinson’s Disease: A Meta‑Analysis of Randomized Controlled Trials

Jamir Pitton Rissardo, Jorge Patino, Ana Fornari Caprara, Ian M. Walker

7 – Efficacy and Safety of Riluzole in Huntington’s Disease: A Systematic Review and Meta‑analysis of Placebo‑Controlled Clinical Trials

Jorge Patino, Jamir Pitton Rissardo, Ana Fornari Caprara, Ian M. Walker

8 – Retinal Structural Changes in Huntington Disease: An OCT‑Based Meta‑analysis

Jorge Patino, Jamir Pitton Rissardo, Ana Fornari Caprara, Ian M. Walker

9 – Three Decades of U.S. Huntington’s Disease Mortality: National Age‑ and Sex‑Specific Trends

Jorge Patino, Jamir Pitton Rissardo, Ana Fornari Caprara, Ian M. Walker

10 – Snowball Effect - How Constipation Associated With Parkinson's Disease Can Lead to Mortality in the Hospital

Salima Brillman, Somil Bhushan

11 – Impact on Tremor in Phase 3 Trials of Tavapadon, a Selective D1/D5 Agonist for Treatment of Parkinson’s Disease

Diego Torres-Russotto, Linda Harmer, Tracy Nicholson, Perminder Bhatia

12 – Levodopa Initiation or Dose Adjustments in TEMPO-4, a 58-Week Open-Label Trial of Tavapadon for Treatment of PD

Tracy Nicholson, William Ondo, Meredith Rollins Hatcher, Michael Soileau, Jim Eubanks, Rohit Dhall

*13 – Pimavanserin in Parkinson’s Disease Psychosis: An Exploratory Post Hoc Delayed-Start Analysis

William G. Ondo, Zoltan Mari, Peter Zhang, Lambros Chrones, Greg Brunson

14 – Boosting Education and Awareness Together for people with Parkinson’s Disease (BEATs-PD): Methodological Considerations in Research Co-Creation

Rebecca Khamishon, Kerry Devlin, Advisory Board BEATs-PD, Kyu Kang, Lauryn Currens, Sarah Phelan, Eojin Choi, Shamera Willoughby, Alex Pantelyat, Kelly Mills

15 – Real-World Comparative Analysis of Falls among Medicare Beneficiaries Newly Diagnosed with Parkinson’s Disease Psychosis initiating Pimavanserin versus Other Atypical Antipsychotics and Quetiapine

Nazia Rashid, Krithika Rajagopalan, Daksha Gopal, Dilesh Doshi, Lambros Chrones

16 – Parkinson’s Disease Related Outcomes among Newly Diagnosed Patients with Parkinson’s Disease Psychosis Treated with Pimavanserin versus Other Atypical Antipsychotics and Quetiapine

Nazia Rashid, Krithika Rajagopalan, Daksha Gopal, Lambros Chrones

17 – Switching to CREXONT® Improves “Good On” Time and Reduces Motor Fluctuations in Parkinson’s Disease: Interim Results from the Real-World ELEVATE-PD Phase 4 Study

Robert Hauser, Stuart Isaacson, Joohi Jimenez-Shahed, Michael Soileau, Andrew Holley, Ghazal Banisadr, Stanley Fisher, Hester Visser

*18 – Switching to CREXONT® (IPX203) Significantly Increases the Duration of “Good On” Intervals

Stuart Isaacson, Leslie Cloud, David Kreitzman, Salima Brillman, Ghazal Banisadr, Stanley Fisher, Robert Hauser

19 – Comparative efficacy of opicapone and entacapone in the management of motor fluctuations in Parkinson’s disease

Fahd Amjad, Sandeep Thakkar, Diogo Martins, Helena Brigas, Bita Naderi, Ghazal Banisadr, Stanley Fisher, Stuart Isaacson

20 – Impact of CREXONT® (IPX203, ER CD-LD) on nighttime sleep in patients with Parkinson’s disease experiencing motor fluctuations: A post-hoc analysis of the RISE-PD trial

Robert Hauser, Alberto Espay, Okeanis Vaou, Jason Aldred, Simon Allard, Ghazal Banisadr, Stanley Fisher'

21 – Cinema Therapy in Parkinson’s Disease: Aesthetic Distance, Narrative Processing, and the Emergence of “Success Stories™”

Robert Cochrane, PhD

22 – Improvisational Play as a Psychosocial Intervention in Parkinson’s Disease

Robert Cochrane, PhD

*23 – Patient and Care Partner Decision-Making Perspectives for Advanced Parkinson’s Disease Therapies

Wei Wei Zhang, Cecilia Jimenez Moreno, Tommi Tervonen, Gemma Al-Jassar, Maria De Leon, Martin Kirchner, Melissa Penn, Tobias Machewitz, Christian de Vries, Anja Gabriel, Jon Weber, Markus Frick, Casper Gøtzsche, Andrea Merriam Crespo, Anissa Mitchell, Jason Lott

27 – Continuous Subcutaneous Apomorphine Infusion (CSAI) Titration Patterns for Patient Starts During the First Six Months of Availability in the United States: Data from the Clinical Nurse Navigator (CNN) Program

Cindy Happel, Andrea Formella, Mindy Grall

28 – European experience with long-term continuous subcutaneous apomorphine infusions at higher doses

Mindy Grall, Jan Parsons, Agnes De Groot, Angel Seasr, Peibing Qin, Marc Verin

*28 – European experience with long-term continuous subcutaneous apomorphine infusions at higher doses

Mindy Grall, Jan Parsons, Agnes De Groot, Angel Seasr, Peibing Qin, Marc Verin

29 – Continuous, Subcutaneous Apomorphine Infusion (CSAI) for PD: Development of a Phase IV routine practice study to capture the patient, care partner, and healthcare professional experience in the United States

Mindy Grall, Alexandra Christiansen, Narayan Maskeri, Sharina Reyes, Peibing Qin, Stuart Isaacson

30 – Improving Motor Function in Advanced Parkinson’s Disease: Outcomes from a Phase III Trial of MR-Guided

Focused Ultrasound

Regina Martuscello, Lindsay Knight, Ian Pyle, Angeles Sanchez Fraga, Natalie Kaempf, Cyril Ferrer, Katie Gant, Augusto Grinspan

*31 – Patient-Reported Burden of HD Chorea and Effect of Deutetrabenazine on Symptom Management and Quality of Life: Results from a Real-World, Decentralized Study

Pooja Gandhi, Daniel Claassen, W. Alex Dalrymple, Stacy Finkbeiner, Diana Klakotskaia, Martijn Konings

32 – A Real-World, Decentralized Study of Caregiver-Reported Burden of Huntington Disease Chorea and Effect of Deutetrabenazine on Symptom Management and Quality of Life

Pooja Gandhi, Karen E. Anderson, Henry P. Moore, Stacy Finkbeiner, Martijn Konings, Diana  Klakotskaia

33 – Expanding Access in Essential Tremor: Outcomes and Adoption of Staged, Bilateral MR-Guided Focused Ultrasound

Ian Pyle, Regina Martuscello, Lindsay Knight, Alan Morris, Angeles Sanchez Fraga, Natalie Kaempf, Cyril Ferrer, Katie Gant, Augusto Grinspan

The following posters will be displayed during Poster Session B on Saturday, June 6 from 11:30 AM-12:00 PM

and the Scientific Exchange Poster Reception on Saturday, June 6 from 6:00 PM-7:30 PM

*Poster Tour B will take place on Saturday, June 6 from 12:00 PM-12:30 PM (posters listed below with a * will be on the tour)

34 – Response Trajectories of Patients With Parkinson’s Disease Psychosis Treated With Pimavanserin: An Exploratory Cluster Analysis

Khashayar Dashtipour, Peter Zhang, Victor Abler, Greg Brunson, Lambros Chrones

35 – Development of ACP-711, a Selective Modulator of GABAA Receptor α3, for Essential Tremor: Use of First-in-Human Phase 1 Pharmacokinetics and Pharmacodynamics to Identify Target Dose/Exposure

Mona Darwish, Nancy Lin, Pierandrea Muglia, Janus Larsen, Caroline Neuray, Massimo Bani, Kelly Maxwell, Robert Hofbauer, Sanjeev Pathak

*36 – Comparative Effectiveness of Tavapadon Versus Real-world Oral Standard of Care Treatments in Parkinson’s Disease With Motor Fluctuations: an Indirect Comparison Analysis

Jim Eubanks, Pinky Agarwal, Rajesh Pahwa, Alfonso Fasano, Huiwen Deng, Connie Yan, Linda Harmer, Susan Huang, Koray Onuk, Alberto Espay

37 – Exploring the Understanding and Communication Patterns of OFF Time Symptoms From a Survey Study of People With Parkinson’s Disease or Their Care Partners

Andrea Merriam, Gina Elsen

38 – Post-Hypoxic Myoclonus (Lance–Adams Syndrome) After Cardiac Arrest in a Young Patient with End-Stage Renal Disease: Management and Clinical Outcomes

Aditi Mohan

39 – Pure Cerebellitis a Rare Presentation of Scrub Typhus Fever

Aditi Mohan

40 – Systematic Review of VPS13D-Associated Movement Disorders: Insights from a Case Report

Juan Sebastián Sánchez León, Leonardo Simao Medeiros, Ingrid Lorena da Silva Gomes, Thomas Hugentobler Schlickmann, Thais Lampert Monte, Gabriela Magalhães Pereira, Laura Bannach Jardim, Artur Francisco Schumacher Schuh

41 – Psychiatric-Onset PLA2G6-Associated Parkinsonism With Early Dyskinesia and Favorable GPi DBS Response

Ingrid Gomes, Juan Sebastián Sánchez León, Daniel Teixeira-dos-Santos, Thomas Hugentobler Schlickmann, Artur Francisco Schumacher Schuh, Thais Lampert Monte, Bruno Fraiman de Oliveira

*42 – Golden Hour Window

Eric Aquino

43 – Empathy in Action: A Sensory Experience for Healthcare Providers

Kelly Papesh, Anissa Mitchell, Clemie Pizzillo

44 – Nilotinib Effects in Lewy Body Disease: A Seven-Year Retrospective Review

Sophia Hu

45 – Factors Affecting Participation in Parkinson’s Disease Community Programs

Chiamaka Onuigbo, Cat Tran, Sofia Martinez, Juan Martinez-Lemus, Shivika Chandra, Mya Schiess

46 – Additive value of Amyloid PET Scan in the Diagnostic Workup and Characterization of Patients with Diffuse Lewy Body Disease

Utsav Kumar, Paula Caro, Fernando Pagan, Yasar Torres-Yaghi

*47 – Efficacy of inhaled levodopa by age-based subgroups in patients with Parkinson's disease: post hoc analysis of pooled data from three phase III trials

Astrid Scheschonka, Margaret Ngure, Carmen Walter, Selena Freisens, Georg Comes

48 – Safety of inhaled levodopa by incidence and severity of treatment-related cough and throat irritation in people with Parkinson’s disease: post hoc analysis of pooled data from three phase III trials

Astrid Scheschonka, Margaret Ngure, Carmen Walter, Selena Freisens, Georg Comes

49 – Episodes of motor and non-motor response fluctuations (OFF episodes) in people with Parkinson’s disease: a targeted qualitative literature review and preliminary patient-centric conceptual model

Astrid Scheschonka, Petra Schwingenschuh, Diego Santos Garcia, Javier Pagonabarraga Mora, Janika Drews, Claudia Ringel

50 – IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy: Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE)

Marta Banach, Iryna Makedonska, Veronika Mykhaylenko, Angelika Hanschmann, Andrzej Dekundy

51 – Recommendations for optimal initial doses of botulinum toxin type A in patients with post-stroke spasticity: An expert consensus

Stephen Ashford, Alessio Baricich, Djamel Bensmail, Bo Biering-Sørensen, Zachary Bohart, Alexandre Camões-Barbosa, Stefano Carda, Damon Hoad, Gabriel

Salazar, Jörg Wissel

*52 – Dual Device-Aided Therapy in Advanced Parkinson’s Disease: A Case Series of Refractory Motor Fluctuations

Paula Caro, Neha Tallapragada, Indrani Biswas, Chloe Posner, Fernando Pagan, Yasar Torres-Yaghi

53 – Using PD Community Clinical Trial Participation Stories to Drive Understanding of Challenges and Barriers to Increasing Diverse Enrollment and Retention in PD Clinical Trial Research

Bernard Coley

*54 – Characterization of “early-start” participants that continued receiving donanemab in the TRAILBLAZER-ALZ 2 long-term extension period

Curtis P. Schreiber, Traci Schilling, Erin G. Doty, Fan Emily Yang, Shoichiro Sato, Jennifer A. Zimmer, Adewale Adeluyi

55 –Evaluating Regional Volumetric MRI Biomarkers and Segmentation Methods for Disease Progression Assessment in Multiple System Atrophy

Benno Gesierich, Marina Mihaljevic, Johannes Levin, Armin Giese, Nitsan Halevy, Steve Barash, Orna Tohami, Werner Poewe, Klaus Seppi, Florian Krismer,

Marco Duering

56 – Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 1 (Parallel-Design Study)

Salima Brillman, Alexander Shtilbans, Jill Farmer, Monique Giroux, Melanie Fridley, Kimberly Crimin, Minao Tang, Taylor Crush, Claudio Santos, Steven Petrou,

Alyssa Wyant, Megan Sniecinski, Marcio Souza

57 – Maintenance of Response and Durability of Effect with Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 2 (Randomized Withdrawal Study)

Jill Farmer, Salima Brillman, Alexander Shtilbans, Monique Giroux, Melanie Fridley, Kimberly Crimin, Minao Tang, Taylor Crush, Claudio Santos, Steven Petrou,

Alyssa Wyant, Megan Sniecinski, Marcio Souza

*58 – Combined Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Results from the Phase 3 Essential3 Program

Alexander Shtilbans, Jill Farmer, Salima Brillman, Monique Giroux, Melanie Fridley, Kimberly Crimin, Minao Tang, Taylor Crush, Claudio Santos, Steven Petrou, Alyssa Wyant, Megan Sniecinski, Marcio Souza

59 – Remote Digital Deployment of a Validated Psychosis Screener in Parkinson's Disease: Real-World Feasibility and Screening Yield

Amanda Hare

60 – A Smartphone-Based Platform for At-Home Motor Assessment

Richard Trosch, Rebekah Griesenauer, Suraj Dhulipalla, Kateryna Konovets